<DOC>
	<DOCNO>NCT02918331</DOCNO>
	<brief_summary>The purpose study evaluate safety daratumumab combine lenalidomide dexamethasone Japanese participant newly diagnose multiple myeloma candidate high-dose chemotherapy autologous stem cell transplantation ( ASCT ) .</brief_summary>
	<brief_title>A Study JNJ-54767414 ( Daratumumab ) Combination With Lenalidomide Dexamethasone Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible High-dose Therapy Autologous Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants document multiple myeloma ( MM ) satisfy CRAB ( calcium elevation , renal insufficiency , anemia , bone abnormality ) criterion , monoclonal plasma cell bone marrow equal ( &gt; = ) 10 percent ( % ) presence biopsy proven plasmacytoma , measurable disease Measurable disease define follow : ( ) immunoglobulin ( Ig ) G MM : serum monoclonal paraprotein ( M protein ) level &gt; =1.0 gram/deciliter ( dL ) urine M protein level &gt; = 200 milligram ( mg ) /24 hour ; ( b ) IgA , IgM , IgD , IgE MM : serum M protein level &gt; =0.5 g/dL urine M protein level &gt; =200 mg/24 hour ; ( c ) Light chain MM without measurable disease serum urine : serum Ig free light chain ( FLC ) &gt; =10 mg/dL abnormal serum Ig kappa lambda FLC ratio Participants newly diagnose consider candidate highdose chemotherapy autologous stem cell transplantation ( ASCT ) due &gt; =65 year old , subject less ( &lt; ) 65 year old presence important comorbid condition ( ) likely negative effect tolerability highdose chemotherapy ASCT Pretreatment clinical laboratory value meet follow criterion Screening Phase Participants must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 A woman childbearing potential must 2 negative serum urine pregnancy test Screening , first within 4 week prior dose second within 3 day prior dose Participants diagnosis primary amyloidosis , monoclonal gammopathy undetermined significance , smolder MM Participant plasma cell leukemia condition Ig ( immunoglobulin ) M protein present absence clonal plasma cell infiltration lytic bone lesion Participants prior current systemic therapy ASCT MM , exception emergency use short course ( equivalent dexamethasone 40 mg/day maximum 4 day ) corticosteroids treatment Participants history malignancy ( MM ) within 5 year date first daratumumab administration Participants radiation therapy within 14 day first dose</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>